Ventricular Myosins

420  relevant articles (4 outcomes, 26 trials/studies) found for this Bio-Agent

Cardiac alpha-Myosin; Cardiac beta-Myosin; Myosin V1; Myosin V2; Myosin V3; Myosin, Ventricular; Ventricular Cardiac alpha-Myosin; Ventricular Cardiac beta-Myosin; Ventricular Isomyosins; Ventricular Myosin; Ventricular alpha, beta- Myosin; Ventricular alpha-Myosin; Ventricular beta-Myosin; alpha-Myosin; beta-Myosin; Cardiac alpha Myosin; Cardiac alpha-Myosin, Ventricular; Cardiac beta Myosin; Cardiac beta-Myosin, Ventricular; Isomyosins, Ventricular; Myosins, Ventricular; Ventricular Cardiac alpha Myosin; Ventricular Cardiac beta Myosin; Ventricular alpha Myosin; Ventricular alpha, beta Myosin; Ventricular beta Myosin; alpha Myosin; alpha-Myosin, Cardiac; alpha-Myosin, Ventricular; alpha-Myosin, Ventricular Cardiac; beta Myosin; beta-Myosin, Cardiac; beta-Myosin, Ventricular; beta-Myosin, Ventricular Cardiac

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sucharov, Carmen C: 3 articles (01/2005 - 08/2003)
2.	Ommen, Steve R: 3 articles (08/2004 - 06/2002)
3.	Gersh, Bernard J: 3 articles (08/2004 - 06/2002)
4.	Tajik, A Jamil: 3 articles (08/2004 - 06/2002)
5.	Will, Melissa L: 3 articles (08/2004 - 06/2002)
6.	Ackerman, Michael J: 3 articles (08/2004 - 06/2002)
7.	Gupta, Madhu: 2 articles (10/2007 - 11/2003)
8.	Zhao, Cai-ming: 2 articles (11/2006 - 03/2006)
9.	Dong, Ning-zheng: 2 articles (11/2006 - 03/2006)
10.	Jiang, Ting-bo: 2 articles (11/2006 - 03/2006)

Related Diseases

1.	Hypertrophy 08/01/1997 - "At matched LA pressure, LA ejection (10.2 +/- 3.0 vs. 17.4 +/- 5.5%), reservoir volume fractions (19 +/- 8 vs. 35 +/- 11%), and heart rate-corrected mean normalized systolic ejection rate (1.25 +/- 0.33 vs. 1.60 +/- 0.44 EF/s) were significantly less, and the volume-normalized diastolic stiffness constant (4.9 +/- 0.8 vs. 3.2 +/- 1.1) was significantly greater, in regression versus control dogs; these changes were associated with incomplete regression of LA hypertrophy and a persistent 77.4% increase in beta-myosin heavy chain (beta-MHC) in the LA body. " 08/01/2009 - "Finally, cardiomyocyte hypertrophy was evaluated by, the expression of beta-myosin heavy chain, alpha-skeletal actin, cell size, and amino acid incorporation. " 07/01/2009 - "Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain." 02/01/2006 - "The activation of the TGF-beta1-TAK1-p38 MAPK pathway paralleled the transcriptional upregulation of cardiac markers for ventricular hypertrophy, beta-myosin heavy chain and atrial natriuretic peptide. " 02/10/2005 - "THF-dTGR and dTGR showed upregulation of hypertrophy markers and alpha/beta-myosin heavy chain switch to the fetal isoform. " Order ALL the reference details at left...
2.	Cardiomegaly (Heart Hypertrophy) 07/01/2008 - "The SHR-MCT group displayed improved cardiac dysfunction [as assessed by left ventricular (LV) end-diastolic pressure and the positive and negative first derivatives of LV pressure/P value], a shift in the beta-myosin heavy chain (MHC)-to-alpha-MHC ratio, and cardiac hypertrophy compared with the SHR-LCT group without an effect on blood pressure. " 06/22/2001 - "In the present study, we examined the role of gp130 in pressure overload-induced cardiac hypertrophy using transgenic (TG) mice, which express a dominant negative mutant of gp130 in the heart under the control of alpha myosin heavy chain promoter. " 07/01/2009 - "AIMS: Cardiac hypertrophy is associated with a reduction in the contractile response to beta-adrenergic stimulation, and with re-expression of foetal genes such as beta-myosin heavy chain (MHC). " 06/01/2009 - "In addition, at a lower frequency, decreased alpha myosin heavy chain was found to give rise to an abnormally looped heart or an enlarged heart. " 08/01/2008 - "Also, none of the pathological cardiac hypertrophy markers, atrial natriuretic peptide, and alphaMHC (alpha-myosin heavy chain)-to-betaMHC ratio, were changed. " Order ALL the reference details at left...
3.	Fibrosis (Cirrhosis) 11/07/2006 - "Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo." 07/23/1999 - "TGII overexpression resulted in a remodeling of the heart with mild hypertrophy, elevated expression of beta-myosin heavy chain and alpha-skeletal actin genes, and diffuse interstitial fibrosis. " 04/27/2007 - "The heart responds to diverse forms of stress by hypertrophic growth accompanied by fibrosis and eventual diminution of contractility, which results from down-regulation of alpha-myosin heavy chain (alphaMHC) and up-regulation of betaMHC, the primary contractile proteins of the heart. " 08/01/1999 - "In striking contrast to truncation mice, however, the R92Q hearts demonstrate significant induction of atrial natriuretic factor and beta-myosin heavy chain transcripts, interstitial fibrosis, and mitochondrial pathology. " 07/17/2001 - "CONCLUSIONS: Simvastatin induced the regression of hypertrophy and fibrosis, improved cardiac function, and reduced ERK1/2 activity in the beta-myosin heavy chain-Q(403) rabbits. " Order ALL the reference details at left...
4.	Hypertrophic Cardiomyopathy (Asymmetric Septal Hypertrophy) 08/01/2006 - "The aim of this study was to identify mutations in the cardiac heavy-chain beta-myosin gene (MYH7b) in a group of Spanish patients with hypertrophic cardiomyopathy. " 06/01/1997 - "This study investigates (1) the in vitro velocities of translocation of fluorescently-labelled actin by beta-myosin purified from soleus muscle of 30 hypertrophic cardiomyopathy patients with seven distinct beta-myosin heavy chain gene mutations: Thr124Ile, Tyr162Cys, Gly256Glu, Arg403Gln, Val606Met, Arg870His, and Leu908Val mutations; and (2) motility activity of beta-myosin purified from cardiac and soleus muscle biopsies in the same patients. " 05/29/2009 - "Hypertrophic cardiomyopathy due to beta-myosin heavy chain mutation with extreme phenotypic variability within a family." 07/18/2008 - "Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone." 04/01/2008 - "Male but not female mice carrying a single R403Q missense allele for cardiac alpha-myosin heavy chain (M-alphaMHC(R403Q/+) and F-alphaMHC(R403Q/+), respectively) develop significant hypertrophic cardiomyopathy (HCM) compared with male and female wild-type mice (M-alphaMHC(+/+) and F-alphaMHC(+/+), respectively) after approximately 30 wk of age. " Order ALL the reference details at left...
5.	Familial Hypertrophic Cardiomyopathy (Cardiomyopathy, Familial Hypertrophic) 02/17/2009 - "Clinical studies have revealed that the D166V mutation in the ventricular myosin regulatory light chain (RLC) can cause a malignant phenotype of familial hypertrophic cardiomyopathy (FHC). " 09/01/2009 - "A novel mutation of the beta myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy." 04/01/2009 - "AIMS: Several mutations in the ventricular myosin regulatory light chain (RLC) were identified to cause familial hypertrophic cardiomyopathy (FHC). " 03/01/2009 - "Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice." 08/01/2008 - "The R403Q mutation in beta-myosin heavy chain was the first mutation to be identified as responsible for familial hypertrophic cardiomyopathy (FHC). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Dobutamine
2.	Simvastatin (Zocor)
3.	glycogen synthase kinase 3 beta
4.	Tropomyosin
5.	Atrial Natriuretic Factor (ANF)
6.	Troponin T (T, Troponin)
7.	Ventricular Myosins
8.	Actins (F Actin)
9.	Proteins (Proteins, Gene)
10.	Isoenzymes

Related Therapies and Procedures

1.	Caloric Restriction
2.	Ligation
3.	Drug Therapy (Chemotherapy)
4.	Transplants (Transplant)
5.	Heart Transplantation (Grafting, Heart)